FIELD: chemistry.
SUBSTANCE: described are novel triazolopyridazines of general formula 
, stereoisomeric or tautomeric forms thereof and physiologically acceptable salts thereof, where Q1 denotes H, -C1-6alkyl, optionally substituted with fluorine, or -C3-6cycloalkyl; Q2 and Q3 independently denote H, -C1-6alkyl; R1-R3 independently denote H, -C1-6 alkyl, -C3-6cycloalkyl, -O-C3-6cycloalkyl, -O-C1-8alkyl, a heterocyclic residue etc; R4-R8 independently denote H, -C1-6 alkyl, -OH, -O-C1-8 alkyl, halogen, SF5 etc, a method for production thereof and use as medicinal agents.
EFFECT: compounds have antithrombotic activity and particularly inhibit the protease-activated receptor.
6 cl, 2 tbl, 242 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TRIAZOLIUM SALT AS RAR1 INHIBITORS, PREPARING THEM AND USING AS DRUG PREPARATION | 2009 |
|
RU2494100C2 |
| CONDENSED TRIAZOLAMINES AS P2X7 MODULATORS | 2010 |
|
RU2533122C2 |
| PHENOXYMETHYL DERIVATIVES | 2016 |
|
RU2746481C1 |
| PHARMACEUTICAL COMBINATIONS CONTAINING PYRIDO[4,3-d]PYRIMIDINE DERIVATIVES AS HSP90 INHIBITOR AND HER2 INHIBITOR | 2009 |
|
RU2532375C2 |
| HETEROARYL-SUBSTITUTED PIPERIDINE DERIVATIVES AS HEPATIC CARNITINE PALMITOYLTRANSFERASE (L-CPT1) INHIBITORS | 2006 |
|
RU2396269C2 |
| COMPOUNDS AND COMPOSITIONS AS CANNABINOID RECEPTOR 1 INHIBITORS | 2005 |
|
RU2431635C2 |
| SUBSTITUTED METHYLPHENYL KETONES SUITABLE FOR USE AS PDE4 INHIBITORS | 2007 |
|
RU2493149C2 |
| PYRIDAZINE DERIVATIVE INHIBITOR, METHOD OF ITS PREPARATION AND ITS USE | 2020 |
|
RU2807611C2 |
| SIGMA-LIGANDS FOR APPLICATION IN PREVENTION AND/OR TREATMENT OF POSTOPERATIVE PAIN | 2011 |
|
RU2569055C2 |
| DERIVATIVES OF DIHYDROBENZO[b][1,4]DIAZEPINE-2-ONE AS I mGluR2 ANTAGONISTS | 2002 |
|
RU2270197C2 |
